Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene. [electronic resource]
Producer: 20200318Description: 139-143 p. digitalISSN:- 2192-4449
- Adult
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Atypical Hemolytic Uremic Syndrome -- drug therapy
- Complement C3b Inactivator Proteins -- metabolism
- Complement Factor H -- metabolism
- Complement Inactivating Agents -- administration & dosage
- Female
- Humans
- Plasmapheresis -- methods
- Pregnancy
- Remission Induction -- methods
- Renal Dialysis -- methods
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.